Le medicament du mois : Preterax, la premiere association fixe faiblement dosee contenant un inhibiteur d'enzyme de conversion et un diuretique thiazide
Arterial hypertension; Drug therapy; Angiotensin converting enzyme inhibitor; Diuretic; Guidelines
Abstract :
[en] Preterax is the first fixed very- low - dose combination of an angiotensin--converting enzyme inhibitor and a diuretic for first line treatment of hypertension. Its antihypertensive efficacy is remarkable due to the presence of 2 drugs with additional effects. The tolerance is also excellent, with adverse effects similar to placebo. The 24 h blood pressure control is maintained. If necessary, the dose can be doubled (BiPreterax). The medical practitioner must keep in mind that it is an association of perindopril 2 mg and indapamide 0.625 mg with their own contra-indications. These low dose associations are now recommended as one of the 2 options to initiate an antihypertensive drug treatment, with the hope of an improvement in the percentage of well controlled blood pressure in the hypertensive population. Let us remember that the blood pressure target to be reached is at least < 140/90 mmHg. Up till now, no antihypertensive class has demonstrated a superiority over the others. Only the blood pressure fall magnitude is important to prevent cardiovascular complications. [fr] Le Preterax® est la première association fixe faiblement dosée contenant un inhibiteur d'enzyme de conversion et un diurétique thiazide disponible pour le traitement de l'hypertension artérielle en première intention (remboursé en B). Son efficacité antihypertensive est remarquable grâce à l'association de deux molécules, bien que faiblement dosées, à action complémentaire. La tolérance est excellente, les effets secondaires très faibles et fort peu différents de ce qu'on observe sous placebo. L'efficacité sur 24 heures et à long terme est conservée. Si nécessaire, la posologie peut être doublée (BiPreterax, remboursé en Bf). Il faut se rappeler qu'il s'agit d'une association fixe faiblement dosée de perindopril 2 mg et d'indapamide 0,625 mg. Les contre-indications relatives à chacun de ces composés sont d'application. Cette association fixe faiblement dosée est recommandée maintenant comme une des deux options en première intention dans le traitement de l'hypertension artérielle. Ce choix permettrait peut-être d'améliorer le pourcentage de patients hypertendus traités atteignant la cible tensionnelle (PA < 140/90 mmHg). Rappelons qu'à ce jour, dans l'hypertension artérielle légère à modérée, aucune classe thérapeutique n'a démontré de supériorité par rapport aux autres. Seule l'efficacité antihypertensive compte dans la prévention du risque cardiovasculaire chez l'hypertendu traité par agents antihypertenseurs.
Disciplines :
Urology & nephrology
Author, co-author :
Krzesinski, Jean-Marie ; Université de Liège - ULiège > Département des sciences cliniques > Néphrologie
Language :
French
Title :
Le medicament du mois : Preterax, la premiere association fixe faiblement dosee contenant un inhibiteur d'enzyme de conversion et un diuretique thiazide
Alternative titles :
[en] The Drug of the Month: A New Antihypertensive Association: Preterax, Low Doses of Ace Inhibitor and Thiazide in the Same Pill
Publication date :
October 2004
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Traitement initial de l'hypertension: état de la question.- Folia Pharmacotherapeutica, 2004, 41, n04, 28-32.
Krzesinski JM.- Nouvelles directives américaines et européennes en 2003 pour la prise en charge de l'hypertension artérielle. Rev Med Liège, 2003, 58, 563-571.
Blood pressure lowering treatment trialists'Collaboration.- Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet, 2003, 362, 1527-1535.
Guidelines Committee.- 2003 European Society of hypertension-European Society of cardiology Guidelines for the management of Arterial Hypertension. J Hypertens, 2003, 21, 1011-1053.
Krzesinski JM.- Qualité de la prise en charge de l'hypertension artérielle. Pouvons-nous, devons-nous faire mieux? Rev Med Liège, 2002, 57, 202-206.
Andréjak M, Laville M, Duru G, et al.- Better efficacy in hypertension management with perindopril/indapamide (PER/IND) strategy compared to sequential or step by step strategies. STRATHE Study: STRAtegies of Treatment in Hypertension: Evaluation. J Hypertens, 2004, 22 (suppl 2), S384.
Krzesinski JM, Rorive M.- Y a-t-il une place d'emblée pour une bithérapie faiblement dosée dans le traitement de l'hypertension artérielle essentielle? Méd et Hyg, 2003, 61, 1556-1559.
Laurent S.- Very-low-dose combination of perindopril and indapamide: efficacy on blood pressure and target-organ damage. J Hypertens, 2003, 21 (suppl 3), S11-S18.
Chalmers J, Castaigne A, Morgan T, et al.- Efficacité au long cours d'une nouvelle association fixe très faiblement dosée IEC/diurétique en traitement de 1 ère intention chez l'hypertendu âgé. J Hypertens, 2000, 18, 327-337.
Chanudet X, De Champvallins M.- Antihypertensive efficacy and tolerability of low-dose perindopril/indapamide combination compared with losartan in the treatment of essential hypertension. Int J Clin Pract, 2001, 55 (4), 233-239.
Mallion JM, Chamontin B, Asmar R, et al.- Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON Study. Am J Hypertens, 2004, 17, 245-251.
Asmar R, London G, O'Rourke M, et al.- Improvement in blood pressure, arterial siffness and wave reflections with a very-low-dose perindopril/ indapamide combination in hypertension patient. A comparison with atenolol. Hypertension, 2001, 38, 922-926.
Dalhöf B. Gosse P, Guéret P. et al.- The P.I.C.X.E.L. Study: benefits of PRETERAX® on LVH reduction. J Hypertens, 2004, 22 (suppl 2), S410.
Mogensen CE, Viberti G, Halimi S, et al.- Effect of low-dose perindopril/indapamide on albumunuria in diabetes. PREterax® in albuMInuria rEgRession: PREMIER. Hypertension, 2003, 41, 1063-1071.
Chalmers J, MacMahon S.- ADVANCE: Action in diabetes and vascular disease-Preterax® and Diamicron® controlled evaluation. Diabetologica, 2001, 44, 1118-1120
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
